Coherus Announces Humira Biosimilar PK Clinical Bioequivalence Results
By EsqSocial Corporation 03/03/17
Yesterday, Coherus announced that CHS-1420, its proposed biosimilar of Humira® (adalimumab), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-1420 to Humira. According to Coherus, the study showed...
By: Goodwin